Osaic Holdings
PMCB icon

Osaic Holdings’s PharmaCyte Biotech PMCB Stock Holding History

Osaic Holdings’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200 Sell
302
-1
-0.3% -$1 ﹤0.01% 7561
2025
Q4 		$219 Sell
303
-1
-0.3% -$1 ﹤0.01% 7568
2025
Q3 		$294 Sell
304
-1
-0.3% -$1 ﹤0.01% 7641
2025
Q2 		$331 Buy
305
+295
+2,950% +$329 ﹤0.01% 7431
2025
Q1 		$12 Sell
10
-527
-98% -$855 ﹤0.01% 7367
2024
Q4 		$841 Buy
537
+29
+6% +$50 ﹤0.01% 6894
2024
Q3 		$969 Sell
508
-5
-1% -$9 ﹤0.01% 6850
2024
Q2 		$1K Sell
513
-1,254
-71% -$2.7K ﹤0.01% 6814
2024
Q1 		$4.19K Buy
1,767
+9
+0.5% +$19 ﹤0.01% 6171
2023
Q4 		$3.8K Sell
1,758
-213
-11% -$462 ﹤0.01% 6273
2023
Q3 		$4.14K Buy
1,971
+213
+12% +$543 ﹤0.01% 6355
2023
Q2 		$5.03K Hold
1,758
– – ﹤0.01% 6304
2023
Q1 		$5.12K Hold
1,758
– – ﹤0.01% 6312
2022
Q4 		$6K Hold
1,758
– – ﹤0.01% 6212
2022
Q3 		$5K Hold
1,758
– – ﹤0.01% 6377
2022
Q2 		$3K Buy
1,758
+1,545
+725% +$3.38K ﹤0.01% 6746
2022
Q1 		$0 Sell
213
-1,550
-88% -$3.44K ﹤0.01% 7429
2021
Q4 		$5K Hold
1,763
– – ﹤0.01% 6648
2021
Q3 		$6K Buy
+1,763
New +$6.2K ﹤0.01% 6455

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Osaic Holdings's PMCB Position: Q1 2026 in Review

Osaic Holdings reduced its PharmaCyte Biotech (PMCB) stake by 0.33% in Q1 2026, selling an estimated $1 and leaving 302 shares worth $200. The position accounts for ﹤0.01% of the portfolio, ranked #7561.

Osaic Holdings first reported a position in PMCB in Q3 2021 and has held it in 19 quarters since. The position peaked at $6K in Q4 2022. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Osaic Holdings held 302 shares of PharmaCyte Biotech worth $200 as of Q1 2026.
  • Osaic Holdings sold 1 PharmaCyte Biotech share in Q1 2026, an estimated $1.
  • PharmaCyte Biotech made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #7561 holding.
  • Osaic Holdings first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 19 quarters since.
  • Osaic Holdings's PharmaCyte Biotech position peaked at $6K in Q4 2022.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.